Prognostic impact of HER family expressions for metastatic colorectal cancer (mCRC): SCRUM-Japan MONSTAR-SCREEN-2 and CALGB/SWOG 80405 trial (Alliance) international collaboration.

Tadayoshi  Hashimoto

No Relationships to Disclose

Yoshiaki  Nakamura

Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda

Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical

Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)

Yan  Yang

No Relationships to Disclose

FRANCESCA  BATTAGLIN

No Relationships to Disclose

Federico  Innocenti

Employment - Abbvie; BeiGene

Stock and Other Ownership Interests  - AbbVie; BeiGene

Patents, Royalties, Other Intellectual Property - United States Patent: "Flavopiridol drug combinations and methods with reduced side effects", Ratain MJ, Innocenti F, Iyer L. Filed on April 12, 2001, serial number 09/835,082.; United States Patent: “Methods of identifying risk of bevacizumab-induced proteinuria and hypertension”, Innocenti F, Quintanilha J, Lin D, Owzar K, Wang J. Filed on July 17, 2020, serial number 16/932,002.; United States Patent: “Optimization of cancer treatment with irinotecan”, Ratain MJ, Innocenti F, Karabatsos P, Grimsley C, Di Rienzo A. Filed on February 12, 2003, serial number 60/446,942.

Alan P.  Venook

Consulting or Advisory Role - Abbvie; Amgen; Exact Sciences; Exelixis; INTERA; Pfizer

Patents, Royalties, Other Intellectual Property - Royalties from Now-UptoDate for authoring and maintaining two chapters

Akitaka  Makiyama

Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda

Consulting or Advisory Role - Lilly Japan

Shogen  Boku

Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; MSD; Taiho Pharmaceutical

Research Funding - Daiichi Sankyo Co. Ltd. (Inst)

Nozomu  Machida

Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha

Research Funding - ALX Oncology (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)

Naoki  Takahashi

No Relationships to Disclose

Shigenori  Kadowaki

Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Merck KGaA; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical

Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst)

Yoshito  Komatsu

Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha

Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha

Toshihiro  Kudo

Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical

Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); Incyte Japan (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)

Eiji  Oki

Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda

Research Funding - Guardant Health

Takeshi  Kato

Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda

Yoshinori  Kagawa

Consulting or Advisory Role - Lilly; Merck; Taiho Pharmaceutical

Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical

Research Funding - Ono Pharmaceutical

Takao  Fujisawa

Honoraria - Amelief; Merck Serono

Hideaki  Bando

Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical

Heinz-Josef  Lenz

Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche

Consulting or Advisory Role - 3T BioSciences; Bayer; BMS; Fulgent Genetics; GlaxoSmithKline; Merck Serono; Roche

Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono

Takayuki  Yoshino

Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda

Consulting or Advisory Role - Sumitomo Corp.

Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)